Last 44 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.66 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 96.26 | — | — | — | — | 36.64 | — | — | — | — | — | 28.87 | — | — | — | — | — | — | — | 321.27 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.22 | — | — | 3.46 | 1.38 | 1.02 | 0.85 | 1.28 | 6.49 | 8.47 | 7.03 | 2.64 | 1.85 | 4.54 | 4.87 | 4.56 | 5.46 | 6.15 | 9.05 | 23.23 | 24.40 |
| — | — | — | +170.9% | -78.7% | -88.0% | -87.9% | -51.5% | +250.6% | +86.7% | +44.4% | -42.3% | -66.1% | -26.3% | -46.2% | -80.4% | -77.6% | -68.8% | -84.7% | -2.0% | -49.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | — | — | — | 100.0% | — | — | — | — | — | 16.1% | — | — | — | — | — | — | — | 100.0% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -13915.9% | — | — | — | — | -2922.1% | — | — | — | — | — | -840.0% | — | — | — | — | — | — | — | -381.9% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -13092.7% | — | — | — | — | -2713.4% | — | — | — | — | — | -807.1% | — | — | — | — | — | — | — | -379.1% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -189.8% | — | -1586.0% | -96.8% | -56.4% | -17.4% | -17.4% | -21.8% | -27.9% | -28.1% | -21.8% | -17.1% | -16.8% | -17.7% | -16.6% | -12.7% | -10.4% | -10.6% | -11.2% | -6.7% | -8.4% |
| — | — | -9009.0% | -344.9% | -101.9% | +38.2% | +20.2% | -27.0% | -66.2% | -58.5% | -31.4% | -35.4% | -61.6% | -67.7% | -48.7% | -88.9% | -24.1% | -42.4% | -12.2% | +30.0% | +25.0% | |
| ROA | -78.0% | -56.5% | -42.1% | -29.6% | -29.2% | -11.1% | -11.7% | -12.8% | -13.5% | -15.0% | -12.2% | -10.0% | -10.2% | -11.3% | -11.2% | -8.9% | -7.4% | -7.5% | -9.0% | -6.0% | -7.6% |
| — | -408.6% | -259.8% | -131.1% | -117.2% | +25.9% | +4.1% | -28.8% | -31.7% | -32.3% | -9.0% | -11.2% | -38.1% | -50.4% | -24.6% | -48.6% | +2.7% | -14.0% | -4.5% | +24.9% | +14.0% | |
| ROIC | -124.2% | -191.6% | -74.8% | -42.0% | -41.2% | -18.3% | -22.3% | -25.3% | -28.2% | -28.1% | -16.6% | -11.1% | -11.3% | -12.6% | -11.9% | -8.4% | -6.3% | -6.4% | -7.8% | -5.4% | -6.6% |
| — | -945.3% | -235.9% | -66.3% | -46.2% | +34.9% | -34.1% | -127.0% | -149.0% | -122.9% | -39.1% | -32.4% | -80.0% | -96.0% | -53.7% | -56.9% | +4.8% | -8.9% | +14.5% | +47.9% | +41.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.30 | — | — | 3.53 | 1.30 | 0.51 | 0.44 | 0.41 | 1.10 | 0.74 | 0.69 | 0.62 | 0.59 | 0.51 | 0.43 | 0.36 | 0.33 | 0.35 | 0.34 | 0.07 | 0.07 |
| — | — | — | +763.1% | +17.7% | -30.9% | -36.7% | -34.0% | +87.2% | +44.9% | +60.8% | +70.7% | +80.6% | +43.5% | +26.5% | +397.7% | +360.7% | +427.0% | +206.7% | -30.4% | -61.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.73 | 0.65 | 1.54 | 3.57 | 5.73 | 5.82 | 7.99 | 9.24 | 5.14 | 4.32 | 3.31 | 3.63 | 5.91 | 7.45 | 8.03 | 12.05 | 14.88 | 13.73 | 18.82 | 20.57 | 20.82 |
| — | -88.9% | -80.7% | -61.4% | +11.5% | +34.9% | +141.7% | +154.3% | -13.0% | -42.0% | -58.9% | -69.9% | -60.3% | -45.8% | -57.3% | -41.4% | -28.5% | -51.9% | +41.5% | +14.8% | +129.7% | |
| Quick Ratio | 5.73 | 0.65 | 1.54 | 3.57 | 5.73 | 5.82 | 7.99 | 9.24 | 5.14 | 4.32 | 3.31 | 3.63 | 5.91 | 7.45 | 8.03 | 12.05 | 14.88 | 13.73 | 18.82 | 20.57 | 20.82 |
| — | -88.9% | -80.7% | -61.4% | +11.5% | +34.9% | +141.7% | +154.3% | -13.0% | -42.0% | -58.9% | -69.9% | -60.3% | -45.8% | -57.3% | -41.4% | -28.5% | -51.9% | +41.5% | +14.8% | +129.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | -21.80 | — | — | — | -0.42 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 44 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADVM stock.
Adverum Biotechnologies, Inc.'s current P/E is -0.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Adverum Biotechnologies, Inc.'s current operating margin is -13915.9%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Adverum Biotechnologies, Inc.'s business trajectory between earnings reports.